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ABSTRACT Staphylococcus aureus is intrinsically resistant to polymyxins (polymyxin
B and colistin), an important class of cationic antimicrobial peptides used in treat-
ment of Gram-negative bacterial infections. To understand the mechanisms underly-
ing intrinsic polymyxin resistance in S. aureus, we screened the Nebraska Transposon
Mutant Library established in S. aureus strain JE2 for increased susceptibility to poly-
myxin B. Nineteen mutants displayed at least 2-fold reductions in MIC, while the
greatest reductions (8-fold) were observed for mutants with inactivation of either
graS, graR, vraF, or vraG or the subunits of the ATP synthase (atpA, atpB, atpG, or
atpH), which during respiration is the main source of energy. Inactivation of atpA
also conferred hypersusceptibility to colistin and the aminoglycoside gentamicin,
whereas susceptibilities to nisin, gallidermin, bacitracin, vancomycin, ciproﬂoxacin, li-
nezolid, daptomycin, and oxacillin were unchanged. ATP synthase activity is known
to be inhibited by oligomycin A, and the presence of this compound increased poly-
myxin B-mediated killing of S. aureus. Our results demonstrate that the ATP synthase
contributes to intrinsic resistance of S. aureus towards polymyxins and that inhibition
of the ATP synthase sensitizes S. aureus to this group of compounds. These ﬁndings
show that by modulation of bacterial metabolism, new classes of antibiotics may
show efﬁcacy against pathogens towards which they were previously considered in-
applicable. In light of the need for new treatment options for infections with serious
pathogens like S. aureus, this approach may pave the way for novel applications of
existing antibiotics.
IMPORTANCE Bacterial pathogens that cause disease in humans remain a serious
threat to public health, and antibiotics are still our primary weapon in treating bac-
terial diseases. The ability to eradicate bacterial infections is critically challenged by
development of resistance to all clinically available antibiotics. Polymyxins constitute
an important class of antibiotics for treatment of infections caused by Gram-
negative pathogens, whereas Gram-positive bacteria remain largely insusceptible to-
wards this class of antibiotics. Here we performed a whole-genome screen among
nonessential genes for polymyxin intrinsic resistance determinants in Staphylococcus
aureus. We found that the ATP synthase is important for polymyxin susceptibility
and that inhibition of the ATP synthase sensitizes S. aureus towards polymyxins. Our
study provides novel insights into the mechanisms that limit polymyxin activity
against S. aureus and provides valuable targets for inhibitors to potentially enable
the use of polymyxins against S. aureus and other Gram-positive pathogens.
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Polymyxins (polymyxin B [PMB] and colistin) are lipopeptide antibiotics that consistof a peptide ring with a three-peptide side chain linked to a fatty acid tail. At
physiological pH, polymyxins are polycationic, which in combination with the fatty acid
tail makes them amphipathic. The amphipathic property of polymyxins promotes
interaction with cell membranes, eventually leading to disruption of membrane integ-
rity and cell death (1). The spectrum of activity of polymyxins is primarily conﬁned to
Gram-negative bacteria (2), where they increase the permeability of the outer mem-
brane and the cytoplasmic membrane (3). Reduced susceptibility to polymyxins in
Gram-negative bacteria can be mediated by reduction of the negative cell surface
charge, which limits the electrostatic interaction between the positively charged poly-
myxins and negatively charged lipopolysaccharides (4).
Polymyxins are generally less active against Gram-positive bacteria (2), and Staph-
ylococcus aureus is intrinsically resistant to PMB and colistin (5). The mechanisms
conferring intrinsic resistance to polymyxins are not completely understood. However,
the sensitivity of S. aureus to structurally different cationic antimicrobial peptides has
been demonstrated to be affected through proteolytic degradation of the human
cathelicidin LL-37 by the protease aureolysin, sequestration of human -defensins by
staphylokinase, alterations of cell surface charge, and active efﬂux of tPMP-1 (thrombin-
induced platelet microbicidal protein 1) by the efﬂux pump QacA (4, 6–8).
In S. aureus, two mechanisms have been demonstrated to alter cell surface charge
in response to the presence of cationic antimicrobial peptides (9, 10). Incorporation of
D-alanine on teichoic acids, mediated by the dltABCD operon, reduces the net negative
charge of the cell surface and thereby reduces electrostatic interaction with cationic
antimicrobial peptides (9). Similarly, incorporation of L-lysine to membrane phosphati-
dylglycerols by the enzyme MprF (FmtC) also reduces the net negative charge (10).
Regulation of the dlt operon andmprF expression is mediated via the three-component
system GraXSR (also known as ApsXSR), which together with the VraFG transporter
system can sense and signal the presence of cationic antimicrobial peptides (6, 11).
Inactivation of graR and vraG has previously been shown to increase the susceptibility
of S. aureus to PMB (12), whereas degradation and sequestration have not been
reported to affect polymyxin susceptibility in S. aureus.
S. aureus is an opportunistic human pathogen that can cause a variety of diseases
ranging from skin infections to life-threatening systemic infections (13). The slow
introduction of novel antimicrobial molecules to the clinic necessitates the understand-
ing of the determinants that make S. aureus intrinsically resistant to polymyxins (14), an
antimicrobial class that is extensively used against Gram-negative infections (1). Knowl-
edge of intrinsic resistance mechanisms could provide targets for helper drugs to
sensitize S. aureus to polymyxins. Therefore, we screened the Nebraska Transposon
Mutant Library (NTML) of 1,920 single-gene inactivations in S. aureus JE2 for mutants
(15), which were unable to grow at subinhibitory concentrations of PMB. The screen
revealed multiple novel polymyxin intrinsic resistance genes, most importantly genes
encoding subunits of the ATP synthase.
RESULTS
The polymyxin B intrinsic resistome. Staphylococcus aureus is intrinsically resistant
to the clinically approved cationic antimicrobial peptides polymyxin B (PMB) and
colistin (1, 16). To identify intrinsic resistance mechanisms in S. aureus, we screened the
entire NTML for mutants that displayed lack of growth on agar plates supplemented
with PMB equal to 0.5 the MIC of the wild type (WT). The MIC for PMB was
subsequently determined using Etests for the identiﬁed mutants. Nineteen mutants
were conﬁrmed to be at least 2-fold more susceptible than the WT (Table 1). As
expected, we identiﬁed transposon insertions in graS, graR, vraF, and vraG, corrobo-
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rating previous work on these determinants in S. aureus in relation to increased PMB
susceptibility (12). Furthermore, transposon insertion in the potassium transporter gene
trkA had a minor effect on PMB susceptibility, as previously observed in Vibrio vulniﬁcus
(17).
Interestingly, inactivation of multiple genes encoding subunits of the ATP synthase
displayed increased sensitivity towards polymyxins: the genes included atpA, atpB,
atpG, and atpH. The ATP synthase generates ATP from ADP and Pi at the F1 domain with
energy derived from proton movement through the Fo domain (18). The F1 domain is
an assembly of ﬁve proteins with the stoichiometry 33111 (18), where atpA
encodes the -subunit, atpG encodes the -subunit, and atpH encodes the -subunit.
The gene atpB encodes the A-subunit of the Fo domain. ATP catalysis proceeds at the
-subunits, whereas the functions of the -subunits remain poorly understood, but
have been shown to be important for attaining maximum activity of the ATP synthase
(19). To the best of our knowledge, the ATP synthase has not previously been associ-
ated with PMB sensitivity in Gram-positive bacteria. However, in Gram-negative bac-
teria such as Escherichia coli, inactivation of atpG increased sensitivity towards colistin
(20), in Proteus mirabilis, a mutant with inactivation of a gene with similarity to one of
the ATP synthase genes displayed increased sensitivity to PMB (21), and in Vibrio
parahaemolyticus, antimicrobial peptide-resistant mutants displayed upregulation of
the ATP synthase F1 -subunit (22).
While we were unable to complement the atpA-inactivated mutant with a functional
atpA gene on a plasmid, we successfully performed allelic exchange of the transposon
insertion with the intact atpA gene, generating a strain displaying PMB sensitivity like
that of the WT (data not shown).
The remaining mutants identiﬁed in the screen only displayed minor increases in
PMB susceptibility (Table 1). For all of the mutants displaying increased susceptibility to
PMB in the NTML, we additionally measured the susceptibility to colistin. Colistin was
less effective against S. aureus JE2 than PMB; however, increased sensitivity to PMB
correlated with increased sensitivity to colistin (Table 1).
Medium composition affects the absolute MIC. It has been reported that growth
medium composition can affect polymyxin MIC (23): therefore, we also tested poly-
myxin B MICs of the WT and atpA, graR, vraG, and vraF mutants by employing the Etest
on cation-adjusted Mueller-Hinton (MH) agar. Polymyxin B displayed greater activity
against S. aureus on MH agar than on tryptic soy agar (TSA) plates; however, the fold
TABLE 1 Intrinsic polymyxin B resistance determinants identiﬁed in the NTML and the
corresponding MICs of polymyxin B and colistin
Gene name Function Gene no.
MIC (g/ml)
Polymyxin B Colistin
Wild type
(S. aureus JE2)
128 256
vraG ABC transporter, permease protein SAUSA300_0648 16 24
vraF ABC transporter, ATP-binding protein SAUSA300_0647 16 32
graR DNA-binding response regulator SAUSA300_0645 16 32
graS Sensor histidine kinase SAUSA300_0646 24 32
atpA ATP synthase F1,  subunit SAUSA300_2060 16 48
atpB FoF1 ATP synthase subunit A SAUSA300_2064 16 48
atpG FoF1 ATP synthase subunit  SAUSA300_2059 16 48
atpH FoF1 ATP synthase subunit  SAUSA300_2061 16 48
cbiO Cobalt transporter ATP-binding subunit SAUSA300_2176 48 64
trkA Potassium uptake protein SAUSA300_0988 48 128
Putative ABC transporter protein EcsB SAUSA300_1785 48 256
vraS Two-component sensor histidine kinase SAUSA300_1866 64 256
yajC Preprotein translocase subunit YajC SAUSA300_1594 64 256
lspA Lipoprotein signal peptidase SAUSA300_1089 64 256
Diacylglycerol glucosyltransferase SAUSA300_0918 64 256
Hypothetical protein SAUSA300_1802 64 256
Hypothetical protein SAUSA300_1254 48 192
Hypothetical protein SAUSA300_0980 48 256
Hypothetical protein SAUSA300_1495 64 256
Polymyxin Intrinsic Resistance in S. aureus ®
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changes between the WT and mutants largely remain identical (see Table S1 in the
supplemental material). Interestingly, strains with inactivation of atpA, graR, vraG, and
vraF are around the breakpoint level of being susceptible according to the guidelines
of CLSI (1, 24). Polymyxin B breakpoints for Pseudomonas aeruginosa are susceptible at
a MIC of 2 g/ml, intermediate at a MIC of 4 g/ml, and resistant at a MIC of 	8
g/ml, whereas for Acinetobacter spp., a MIC of 	4 g/ml is considered resistant.
D-Alanylation of teichoic acids and lysinylation of phosphatidylglycerols. No
mutants with inactivation of genes in the dltABCD operon exist in the NTML (15);
however, incorporation of D-alanine on teichoic acids mediated by the dltABCD operon
has previously been revealed to affect susceptibility to cationic antimicrobial peptides
(9). Therefore, we examined PMB susceptibility of an isogenic strain pair, namely, an
SA113 ΔdltA mutant (PMB MIC, 48 g/ml) relative to the WT parent strain, SA113 (PMB
MIC, 512 g/ml) (see Table S2 in the supplemental material). The result shows that
D-alanylation of teichoic acids also is mediating resistance to PMB.
By screening the NTML, the mutant with inactivation of mprF did not display
increased sensitivity to PMB, and to conﬁrm this result, we tested PMB susceptibility of
the SA113 ΔmprF mutant (PMB MIC, 384 g/ml) relative to ancestral WT strain SA113
(PMB MIC, 512 g/ml) (Table S2). This suggests that lysinylation of phosphatidylglycerol
is not an intrinsic PMB resistance mechanism, in contrast to other classes of cationic
antimicrobial peptides (10, 25). Lysinylation of phosphatidylglycerols therefore seems
to mediate selective protection against certain cationic antimicrobial peptides.
Inactivation of atpA confers hypersusceptibility to gentamicin. We assessed
whether an impaired ATP synthase affected susceptibility to other antimicrobial pep-
tides (Table 2) and conventional antimicrobial agents (Table 3) by comparing the atpA
mutant with the WT, as well as the established determinants vraG, vraF, and graR. Only
marginal changes in susceptibility to the antimicrobial peptides bacitracin, gallidermin,
and nisin, were detected for all of the mutants (Table 2). The vraF and graR mutants
displayed at least 2-fold increased sensitivity to the human cathelicidin LL-37, whereas
atpA was indistinguishable from the WT (Table 2). For conventional antimicrobial
agents, minor reductions in vancomycin MIC were observed for vraG, vraF, and graR
mutants, but not for the atpA mutant. The vraG, vraF, and graR mutants displayed
increased sensitivity to gentamicin (3- to 6-fold), whereas atpA displayed a 16-fold
increased sensitivity (Table 3). Contrarily, no differences in sensitivities between all the
mutants and the WT were detected for ciproﬂoxacin, linezolid, oxacillin, and daptomy-
cin (Table 3). Increased susceptibility of the atpA mutant was restricted to polymyxins
and aminoglycosides, demonstrating that the ATP synthase is not generally involved in
reducing antimicrobial activity of cationic antibiotics or antimicrobial peptides.
TABLE 2 MICs of antimicrobial peptides for the wild type and selected mutants
Peptide Charge
MIC (g/ml)
WT vraG atpA vraF graR
Gallidermin Cationic 16 8 16 8 8
Nisin Cationic 512 256 256 256 256
LL-37 Cationic 128 128 128 64 64
Bacitracin Neutral 256 256 128 256 128
TABLE 3 MICs of conventional antibiotics for the wild type and selected mutants
Antibiotic Charge
MIC (g/ml)
WT vraG atpA vraF graR
Ciproﬂoxacin Neutral 32 32 32 32 32
Oxacillin Anionic 0.5 0.50 0.500 0.50 0.50
Linezolid Neutral 2 2 2 2 2
Gentamicin Cationic 1.5 0.25 0.094 0.38 0.50
Vancomycin Cationic 1.5 1 1.500 0.75 1
Daptomycin Cationic 0.25 0.25 0.250 0.25 0.19
Vestergaard et al. ®
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The atpA mutant displays hyperpolarization of the membrane. The magnitude
of the membrane potential can have a large effect on the activity of antimicrobial
peptides against different bacterial species (26). It has been hypothesized that due to
the negative orientation of the membrane potential, cationic antimicrobial peptides are
electrophoretically drawn into the nonpolar membrane (26). Furthermore, uptake of
gentamicin into the cell is dependent on membrane potential, where hyperpolarization
of the membrane increases uptake, while depolarization reduces uptake (27).
We therefore hypothesized that the atpA mutant was more susceptible to PMB due
to hyperpolarization of the membrane in the absence of ATP synthase activity. Hence,
we assessed the membrane potential for the atpA mutant using the ﬂuorescent dye
DiOC2 (3), and indeed, the atpA mutant displayed hyperpolarization of the membrane
(Fig. 1). This corroborates a previous study on an ATP synthase-deﬁcient ΔFoF1 mutant
strain of Corynebacterium glutamicum, which also displayed increased membrane po-
tential relative to the wild type (28).
Cell surface charge remains unchanged for the atpA mutant. A change toward
a less negative cell surface charge has previously been correlated with a decrease in
susceptibility to cationic antimicrobial peptides (9, 29–31). To assess the potential
correlation between cell surface charge and sensitivity to PMB in our mutants, we
measured the zeta potential of the atpA, vraG, graR, and vraF mutants and the WT
(Fig. 2). No signiﬁcant changes in zeta potentials were detected. Furthermore, we could
not detect any signiﬁcant differences between the atpA mutant and the WT for
FIG 1 Membrane potentials of the WT (JE2) and atpA mutant when assayed with the ﬂuorescent dye
DiOC2 (3). The atpA mutant displayed hyperpolarization of the membrane after 5 min of staining. The
data represent the average from three measurements, with errors bars showing 95% conﬁdence
intervals. The black star indicates signiﬁcant difference at P  0.05.
FIG 2 Zeta potential of the WT (JE2) and selected mutants. No signiﬁcant changes in zeta potential were
detected between the wild type and tested mutants. The data represent the average from six measure-
ments, with errors bars showing 95% conﬁdence intervals.
Polymyxin Intrinsic Resistance in S. aureus ®
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D-alanine content on teichoic acids (Fig. 3) or for the relative content of lysinylated
phosphatidylglycerols in the membrane (data not shown).
Inhibition of the ATP synthase increases efﬁcacy of polymyxin B. The ATP
synthase is a well-described protein complex, and multiple inhibitors have been
identiﬁed that interfere with its function—e.g., the macrolide oligomycin A (32). To
demonstrate the potential of the ATP synthase as a target for potentiating the efﬁcacy
of polymyxins against S. aureus, we assessed the killing efﬁcacy of PMB in the presence
or absence of the ATP synthase inhibitor oligomycin A (Fig. 4). At a concentration of
PMB equal to 0.25 the MIC of the WT, the combination therapy (PMB plus oligomycin
A) reduced the colony-forming units (CFU) 60-fold after 4 h for the WT, whereas
continued growth was observed for WT with treatment with PMB alone. The combi-
natory efﬁcacy of PMB and oligomycin A is similar to the observed killing efﬁcacy of
PMB against the atpA mutant. Oligomycin A alone at the provided concentration
(8 g/ml) did not display any killing efﬁcacy against S. aureus.
DISCUSSION
The limited availability of effective and well-tolerated therapies for antibiotic-
resistant S. aureus has led to a search for inhibitors to improve the efﬁcacy of existing
antibiotic compounds by targeting acquired and intrinsic resistance mechanisms (33–
36). Inhibition of wall teichoic acid synthesis restored -lactam efﬁcacy against
methicillin-resistant S. aureus (33) and ﬂuoroquinolone efﬁcacy was increased by inhi-
bition of the efﬂux pump NorA (35, 36). These studies, however, have focused on
potentiating the efﬁcacy of antibiotics that are normally used against staphylococcal
infections and have not included antibiotics that S. aureus is intrinsically resistant
against.
The present study provides the ﬁrst whole-genome overview of intrinsic polymyxin
resistance genes in S. aureus. Most importantly, we identiﬁed the ATP synthase as a
novel target for potentiating the efﬁcacy of polymyxins against S. aureus. Inhibition of
the ATP synthase potentiates equally well the efﬁcacy of polymyxins against S. aureus
as inactivation of the previously established two-component system GraSR and the
VraFG transporter system (Table 1).
The bacterial ATP synthase has been validated as an antimicrobial target with the
recent approval of the antituberculosis agent bedaquiline (14). Bedaquiline selectively
targets the subunit c of the ATP synthase in most mycobacteria, while displaying
limited or no activity against other bacterial pathogens, including S. aureus (37).
Derivatives of the diarylquinoline scaffold of bedaquiline have been generated to
increase the activity towards other important Gram-positive pathogens (e.g., S. aureus),
while still displaying limited or no activity against Gram-negative bacteria (38). Chem-
ical inhibition of the ATP synthase with oligomycin A signiﬁcantly increased the
FIG 3 D-Alanylation of teichoic acids. No statistical difference on D-Ala content in teichoic acids between
the WT (JE2) and selected mutants. The data represent the average from three measurements, with error
bars showing 95% conﬁdence intervals.
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antistaphylococcal activity of PMB (Fig. 4). However, oligomycin A is nonselective and
therefore also inhibits the mitochondrial ATP synthase (38), rendering it inappropriate
for human use. Numerous other compounds have been identiﬁed that interact with
ATP synthases (32), which can be explored as potentiators of polymyxins and amino-
glycosides in S. aureus for human use. The ATP synthase also constitutes a potential
target for potentiation of polymyxins against Gram-negative bacteria, as inactivation of
atpG in E. coli increased sensitivity towards colistin (20).
Inactivation of the ATP synthase conferred hyperpolarization of the membrane
(Fig. 1), and we propose this as a potential mechanism for the improved activity of
polymyxins. Increased membrane potential may correlate with increased activity of
other cationic antimicrobial peptides (26). Furthermore, deletion of the gene phoP in
E. coli conferred hyperpolarization of the membrane and a concomitant increase in
activity of PMB, while collapsing the proton gradient with m-chlorophenyl carbonyl
cyanide hydrozone (CCCP) abrogated this effect (39).
The spectrum of activity of polymyxins also indicates the interrelatedness of the
electron transport chain with polymyxin activity, as polymyxins generally display
bactericidal activity against Gram-negative bacteria, except against anaerobic Gram-
negative bacteria (23, 40, 41). The killing efﬁciency of polymyxins against P. aeruginosa
has been reported to be diminished under anaerobic compared to aerobic conditions
(42); however, another study could not conﬁrm this (43).
The interrelatedness of the ATP synthase and membrane potential with polymyxin
susceptibility is not yet completely understood; however, we have demonstrated that
the ATP synthase is a potential target for sensitizing S. aureus towards polymyxins. The
ATP synthase may also be targeted for potentiating the efﬁcacy of aminoglycosides and
potentially other cationic antimicrobial peptides not tested in this study.
Taken together, a greater understanding of the mechanisms conferring intrinsic
resistance can provide novel targets for development of inhibitors to potentiate the
efﬁcacy of polymyxins and thereby potentially broaden the spectrum of activity of this
class of antibiotics to important Gram-positive pathogens. With the need for new
treatment options for infections with serious pathogens like S. aureus, targeting intrin-
sic resistance mechanisms may pave the way for novel applications of existing antibi-
otics.
MATERIALS AND METHODS
Bacterial strains, growth conditions, and MIC determination. The strains used in this study
include S. aureus strain JE2 (plasmid-cured derivative of USA300 LAC) and all derivative strains within the
Nebraska Transposon Mutant Library (NTML), consisting of 1,920 unique transposon mutants with
inactivation of nonessential genes (15). The bursa aurealis transposon used to create the collection
contains the resistance cassette ermB, which confers resistance to erythromycin (15). Additionally we
used S. aureus SA113 and two derivatives, SA113 ΔdltA (9) and SA113 ΔmprF (10). All bacterial strains
FIG 4 Improved killing efﬁcacy of PMB upon inhibition of the ATP synthase. Antibacterial activities of
polymyxin B (0.25MIC) alone or in combination with the ATP synthase inhibitor oligomycin A (8 g/ml)
were assayed against the WT. As a control of the target, the killing efﬁcacy of polymyxin B (0.25 MIC)
was determined for the atpA mutant. The data represent the average from three measurements, with
error bars showing 95% conﬁdence intervals.
Polymyxin Intrinsic Resistance in S. aureus ®
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were cultured at 37°C in tryptic soy broth (TSB) or on tryptic soy agar (TSA), with antimicrobial agents
added as indicated. Two methods have been employed to determine MICs to various antimicrobial
agents. (i) A 2-fold broth microdilution assay in TSB (100 l) with an initial inoculum of approximately 5
105 cells/ml was employed to determine the MICs of polymyxin B sulfate (Sigma), gallidermin (Santa Cruz
Biotechnology), nisin (Sigma), bacitracin (Sigma), and LL-37 (Isca Biochemicals). (ii) An Etest (BioMérieux)
performed on TSA plates was employed to determine MICs for polymyxin B, colistin, ciproﬂoxacin,
oxacillin, linezolid, gentamicin, vancomycin, and daptomycin. The MIC was determined upon incubation
at 37°C for 22 h. When indicated, the Etest (BioMérieux) was performed on Mueller-Hinton agar plates
(cation adjusted for calcium and magnesium).
Screening for increased polymyxin B susceptibility. The NTML is stored in glycerol at 80°C in 20
96-well microtiter plates. Material from the frozen stock was transferred directly with a Deutz 96
cryoreplicator (44) from the 96-well microtiter plates onto TSA plates supplemented with 5 g/ml
erythromycin (as all the strains in the NTML are resistant to erythromycin [15]) and 64 g/ml polymyxin
B (0.5 the MIC). The plates were incubated at 37°C for 24 h and visually inspected for lack of growth
of individual mutants.
Zeta potential. Overnight cultures were incubated at 37°C with orbital shaking at 180 rpm,
harvested by centrifugation at 4,600  g for 10 min, and suspended in phosphate-buffered saline (PBS:
10 mM phosphate buffer, 2.7 mM potassium chloride, 137 mM sodium chloride) to a density of 2.8 108
to 4.6  108 cells/ml. Zeta potentials were measured at 25°C with a Zetasizer Nano ZS (Malvern
Instruments) using folded capillary cells (Malvern Instruments). Six measurements were taken for each
sample, and zeta potentials were calculated using the Smoluchowski equation with Zetasizer software
(v7.02).
Assessment of membrane potential measurements using ﬂow cytometry. Membrane potential
was assessed using a ﬂow cytometry assay based on the BacLight bacterial membrane potential kit (Life
Technologies). Cells from overnight cultures were inoculated in 10 ml TSB in 100-ml Erlenmeyer ﬂasks
and grown to an optical density at 600 nm (OD600) of 0.2. Fifteen microliters of culture was transferred
to 1 ml ﬁltered PBS. To each cell solution, 10 l of the ﬂuorescent membrane potential indicator dye
DiOC2 (3) was added and cells were stained for 5 min at room temperature. Data were recorded on a BD
Biosciences Accuri C6 ﬂow cytometer (Becton, Dickinson and Company), with emission ﬁlters suitable for
detecting red and green ﬂuorescence. Settings on the ﬂow cytometer were as follows: 50,000 recorded
events at a forward scatter (FSC) threshold of 15,000 and medium ﬂow rate. Gating of the stained cell
population and analysis of ﬂow cytometry data were performed in CFlow (BD Accuri). As an indicator of
membrane potential, the ratio of red to green ﬂuorescence intensity was calculated. The assay was
veriﬁed with the NTML mutant containing a transposon insertion in menD (NE1345), which displays
depolarization of the membrane (45).
Chromosomal reconstruction of atpA. Chromosomal reconstruction of the atpA mutant was
achieved by use of the temperature-sensitive shuttle vector pBASE6 (46). A chromosomal region
encompassing atpA was PCR ampliﬁed from WT S. aureus JE2 chromosomal DNA using primer pair
5=-ATATGAGCTCGAAGAGTTAGATAAGATTGTCAAACTAG-3= and 5=-GATACAAGATCTGATGGTTTGTATTGCT
ACTTGC-3= and cloned into pBASE6 via SacI/BglII. This plasmid was puriﬁed from E. coli IM08B (47) and
transformed directly into JE2 atpA::N (NE592) at 30°C followed by chromosomal integration by plating
on TSA (10 g/ml chloramphenicol) at 44°C overnight. Plasmid cross-out was performed by passage at
30°C followed by plating on TSA (500 ng/ml anhydrotetracycline), and successful allelic exchange of the
transposon insertion with the intact atpA gene was selected for by replica plating of colonies and
screening for sensitivity toward erythromycin and chloramphenicol. Reconstruction of the atpA locus was
veriﬁed by PCR ampliﬁcation using primers 5=-CAAGTATGCTAAAGCATTATTTGACGTGTC-3= and 5=-CGTA
ATTTCTGCTTGTCTCGCTCTG-3= positioned outside the chromosomal region used for homologous recom-
bination.
Kill curve experiment assessing polymyxin B efﬁcacy upon inhibition of the ATP synthase.
From overnight cultures of S. aureus JE2 and the derivative atpA mutant, 100 l was diluted into 900 l
fresh TSB medium in a Falcon tube and grown for 1 h for the cells to reach the early exponential phase.
After 1 h, the cultures were diluted into 10 ml fresh TSB medium in 100-ml Erlenmeyer ﬂasks, reaching
an initial cell count of approximately 106 cells/ml. Oligomycin A (Sigma) was added to ﬂasks as indicated
at a concentration of 8 g/ml. After 30 min of growth, polymyxin B was added to ﬂasks as indicated at
a concentration equal to 0.25 the MIC. CFU were determined on TSA plates before addition of
oligomycin A (time zero [T0]), before addition of polymyxin B (time 30 min [T30]), and every hour for the
following 4 h.
Analysis of D-alaninylation of the S. aureus cell envelope. S. aureus JE2 and the mutant strains
were grown to the early stationary phase (6 h), washed with ammonium acetate buffer (20 mM), and
adjusted to an OD600 of 30 in a total volume of 1 ml. Cells were taken up in NaOH to a ﬁnal volume of
100 l and were incubated for 1 h of shaking at 37°C to hydrolyze the D-alanine esters. The reaction was
stopped with 100 l of HCl, and the precipitated cell debris was removed by centrifugation and sterile
ﬁltration. D-Alanine was derivatized with ortho-phthaldialdehyde (OPA), similar to previous experiments
(48). Five microliters OPA and 5 l substrate were mixed for 120 s, and the reaction was stopped by
adding 3 l 100% acetic acid. The sample was then separated via ultraperformance liquid chromatog-
raphy (UPLC) with an Acquity H class UPLC system from Waters. Five microliters sample was run on a
gradient in 24 min from 100% buffer A (25 mM sodium phosphate buffer, pH 7.2) to 100% buffer B (45%
acetonitrile, 45% methanol, 10% H2O) in a stepwise manner. The column temperature was 23°C, and the
ﬂow rate was 0.32 ml/min. Fluorescence was detected at 338 nm.
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Isolation and quantiﬁcation of polar lipids. Polar lipids were isolated from S. aureus cultures grown
to the logarithmic phase (OD600 of 0.8) and extracted with chloroform-methanol-sodium acetate buffer
(20 mM) (1:1:1 by volume) by the Bligh-Dyer method (49), vacuum dried, and dissolved in chloroform-
methanol (2:1 by volume). Amino group- or phosphate group-containing lipids were detected by
ninhydrin or molybdenum blue staining, respectively. Aminoacyl phospholipids were quantiﬁed in
relation to total phospholipid content by determining lipid spot intensities of molybdenum blue-stained
lipids as described recently (50).
Statistics. The data were analyzed in GraphPad Prism 7 (GraphPad Software, Inc.) using one-way
analysis of variance (ANOVA) with a post hoc analysis of Dunnett’s multiple comparison tests, where P 
0.05 is considered signiﬁcant (highlighted with a black star in Fig. 1).
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